Valuation: Actuate Therapeutics, Inc.

Market Cap 23.9M 20.81M 19.64M 17.84M 33.42M 2.29B 33.58M 235M 90.73M 1.17B 89.77M 87.78M 3.75B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 23.9M 20.81M 19.64M 17.84M 33.42M 2.29B 33.58M 235M 90.73M 1.17B 89.77M 87.78M 3.75B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
84.59%
Yield 2026 *
-
Yield 2027 * -
1 day-1.41%
1 week-14.68%
Current month-35.45%
1 month-0.89%
3 months-52.14%
6 months-64.58%
Current year-83.97%
1 week 0.94
Extreme 0.94
1.09
1 month 0.94
Extreme 0.94
1.97
Current year 0.9
Extreme 0.9
7.05
1 year 0.9
Extreme 0.9
8.49
3 years 0.9
Extreme 0.9
11.99
5 years 0.9
Extreme 0.9
11.99
10 years 0.9
Extreme 0.9
11.99
Manager TitleAgeSince
Chief Executive Officer 64 28/02/2015
Director of Finance/CFO 58 31/01/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 64 31/03/2015
Chairman 46 31/03/2015
Director/Board Member 66 28/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
14/08/26 Exercice

Chief Executive Officer

664,633 2.7779%
21/05/26 Free

Director

15,000 0.0633%
21/05/26 Free

Director

15,000 0.0633%
Change 5-day change 1-year change 3-year change Capi.($)
-1.41%-14.68%-85.82% - 23.9M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-5.72%-17.12%+350.96% 27.07B
-2.64%-0.35%-2.13%-15.04% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+1.62%+44.31%+167.58% 14.49B
+0.73%+5.00%-1.33%+854.55% 14.14B
-0.54%-0.30%+27.33%+202.19% 12.35B
Average -0.78%+0.17%+24.91%+223.74% 26.22B
Weighted average by Cap. -0.59%+1.39%+35.78%+161.34%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Employees
-
Date Price Change Volume
18/09/26 US$0.9812 -1.41% 113,077
17/09/26 US$0.9952 -0.22% 174,595
16/09/26 US$0.9974 +1.39% 208,826
15/09/26 US$0.9837 -4.50% 148,445
14/09/26 US$1.030 -3.74% 259,021
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9952USD
Average target price
11.68USD
Spread / Average Target
+1,073.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACTU Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!